Publication
2023
- Mundy, R. M. et al. 2023. Broad sialic acid usage amongst species D human adenovirus. npj Viruses 1, article number: 1. (10.1038/s44298-023-00001-5)
2022
- Bates, E. A. et al. 2022. Development of a low seroprevalence, αvβ6 integrin selective virotherapy based on human adenovirus type 10. Molecular Therapy - Oncolytics 25, pp. 43-56. (10.1016/j.omto.2022.03.007)
2019
- Baker, A., Mundy, R. M., Davies, J. A., Rizkallah, P. and Parker, A. L. 2019. Human adenovirus type 26 uses sialic acid - bearing glycans as a primary cell entry receptor. Science Advances 5(9), article number: eaax3567. (10.1126/sciadv.aax3567)
Articles
- Mundy, R. M. et al. 2023. Broad sialic acid usage amongst species D human adenovirus. npj Viruses 1, article number: 1. (10.1038/s44298-023-00001-5)
- Bates, E. A. et al. 2022. Development of a low seroprevalence, αvβ6 integrin selective virotherapy based on human adenovirus type 10. Molecular Therapy - Oncolytics 25, pp. 43-56. (10.1016/j.omto.2022.03.007)
- Baker, A., Mundy, R. M., Davies, J. A., Rizkallah, P. and Parker, A. L. 2019. Human adenovirus type 26 uses sialic acid - bearing glycans as a primary cell entry receptor. Science Advances 5(9), article number: eaax3567. (10.1126/sciadv.aax3567)
Supervisors
Alan Parker
Professor of Translational Virotherapies. Head of Section of Solid Cancers, Division of Cancer and Genetics